An in vivo accelerated developmental myelination model for testing promyelinating therapeutics.
Diffusion tensor imaging
ELISA
Fractional anisotropy
MRI
Promyelinating
Rat
Resonance Raman spectroscopy
Thyroxine
Journal
BMC neuroscience
ISSN: 1471-2202
Titre abrégé: BMC Neurosci
Pays: England
ID NLM: 100966986
Informations de publication
Date de publication:
25 05 2022
25 05 2022
Historique:
received:
30
07
2021
accepted:
10
05
2022
entrez:
25
5
2022
pubmed:
26
5
2022
medline:
28
5
2022
Statut:
epublish
Résumé
Therapeutic agents stimulating the process of myelination could be beneficial for the treatment of demyelinating diseases, such as multiple sclerosis. The efficient translation of compounds promoting myelination in vitro to efficacy in vivo is inherently time-consuming and expensive. Thyroid hormones accelerate the differentiation and maturation of oligodendrocytes, thereby promoting myelination. Systemic administration of the thyroid hormone thyroxine (T4) accelerates brain maturation, including myelination, during early postnatal development. The objective of this study was to validate an animal model for rapid testing of promyelinating therapeutic candidates for their effects on early postnatal development by using T4 as a reference compound. Daily subcutaneous injections of T4 were given to Sprague Dawley rat pups from postnatal day (PND) 2 to PND10. Changes in white matter were determined at PND10 using diffusion tensor magnetic resonance imaging (DTI). Temporal changes in myelination from PND3 to PND11 were also assessed by quantifying myelin basic protein (MBP) expression levels in the brain using the resonance Raman spectroscopy/enzyme-linked immunosorbent assay (RRS-ELISA) and quantitative immunohistochemistry. DTI of white matter tracts showed significantly higher fractional anisotropy in the internal capsule of T4-treated rat pups. The distribution of total FA values in the forebrain was significantly shifted towards higher values in the T4-treated group, suggesting increased myelination. In vivo imaging data were supported by in vitro observations, as T4 administration significantly potentiated the developmental increase in MBP levels in brain lysates starting from PND8. MBP levels in the brain of animals that received treatment for 9 days correlated with the FA metric determined in the same pups in vivo a day earlier. Furthermore, accelerated developmental myelination following T4 administration was confirmed by immunohistochemical staining for MBP in coronal brain sections of treated rat pups. T4-treated rat pups had increased MBP expression levels and higher MRI fractional anisotropy values, both indications of accelerated myelination. This simple developmental myelination model affords a rapid test of promyelinating activity in vivo within several days, which could facilitate in vivo prescreening of candidate therapeutic compounds for developmental hypomyelinating diseases. Further research will be necessary to assess the utility of this platform for screening promyelination compounds in more complex demyelination disease models, such us multiple sclerosis.
Sections du résumé
BACKGROUND
Therapeutic agents stimulating the process of myelination could be beneficial for the treatment of demyelinating diseases, such as multiple sclerosis. The efficient translation of compounds promoting myelination in vitro to efficacy in vivo is inherently time-consuming and expensive. Thyroid hormones accelerate the differentiation and maturation of oligodendrocytes, thereby promoting myelination. Systemic administration of the thyroid hormone thyroxine (T4) accelerates brain maturation, including myelination, during early postnatal development. The objective of this study was to validate an animal model for rapid testing of promyelinating therapeutic candidates for their effects on early postnatal development by using T4 as a reference compound.
METHODS
Daily subcutaneous injections of T4 were given to Sprague Dawley rat pups from postnatal day (PND) 2 to PND10. Changes in white matter were determined at PND10 using diffusion tensor magnetic resonance imaging (DTI). Temporal changes in myelination from PND3 to PND11 were also assessed by quantifying myelin basic protein (MBP) expression levels in the brain using the resonance Raman spectroscopy/enzyme-linked immunosorbent assay (RRS-ELISA) and quantitative immunohistochemistry.
RESULTS
DTI of white matter tracts showed significantly higher fractional anisotropy in the internal capsule of T4-treated rat pups. The distribution of total FA values in the forebrain was significantly shifted towards higher values in the T4-treated group, suggesting increased myelination. In vivo imaging data were supported by in vitro observations, as T4 administration significantly potentiated the developmental increase in MBP levels in brain lysates starting from PND8. MBP levels in the brain of animals that received treatment for 9 days correlated with the FA metric determined in the same pups in vivo a day earlier. Furthermore, accelerated developmental myelination following T4 administration was confirmed by immunohistochemical staining for MBP in coronal brain sections of treated rat pups.
CONCLUSIONS
T4-treated rat pups had increased MBP expression levels and higher MRI fractional anisotropy values, both indications of accelerated myelination. This simple developmental myelination model affords a rapid test of promyelinating activity in vivo within several days, which could facilitate in vivo prescreening of candidate therapeutic compounds for developmental hypomyelinating diseases. Further research will be necessary to assess the utility of this platform for screening promyelination compounds in more complex demyelination disease models, such us multiple sclerosis.
Identifiants
pubmed: 35614392
doi: 10.1186/s12868-022-00714-y
pii: 10.1186/s12868-022-00714-y
pmc: PMC9134688
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
30Informations de copyright
© 2022. The Author(s).
Références
Acta Neuropathol. 2017 Feb;133(2):223-244
pubmed: 27766432
Neurobiol Aging. 2018 Jan;61:44-51
pubmed: 29032192
Mol Cell Neurosci. 2012 May;50(1):45-57
pubmed: 22472204
Oxid Med Cell Longev. 2020 May 12;2020:7191080
pubmed: 32454942
Exp Neurol. 2012 May;235(1):357-67
pubmed: 22421533
J Neurochem. 1981 May;36(5):1792-801
pubmed: 7241137
Neuroimage. 2013 Jun;73:239-54
pubmed: 22846632
Thyroid. 2018 Nov;28(11):1434-1442
pubmed: 30259797
Curr Protoc Cell Biol. 2018 Jun;79(1):e49
pubmed: 29924487
Radiology. 2012 Apr;263(1):235-42
pubmed: 22438446
Genes Brain Behav. 2021 Jan;20(1):e12663
pubmed: 32372528
Neuroimage. 2013 Oct 1;79:329-39
pubmed: 23648962
Neurology. 2019 Mar 12;92(11):519-533
pubmed: 30787160
Neuropathol Appl Neurobiol. 1982 Sep-Oct;8(5):365-75
pubmed: 7177337
Ther Adv Neurol Disord. 2020 Jul 31;13:1756286420945135
pubmed: 33029200
Mol Neurobiol. 2016 Sep;53(7):4406-16
pubmed: 26243185
Dev Med Child Neurol. 2010 May;52(5):475-82
pubmed: 19811520
F1000Res. 2019 Jan 29;8:117
pubmed: 31069065
Commun Biol. 2019 Mar 26;2:116
pubmed: 30937398
Curr Opin Neurol Neurosurg. 1993 Jun;6(3):379-86
pubmed: 8507907
Front Psychiatry. 2020 Apr 30;11:379
pubmed: 32425837
Eur J Pharmacol. 1993 Jun 11;237(1):9-16
pubmed: 8359210
Ann Clin Transl Neurol. 2019 Sep;6(9):1905-1922
pubmed: 31392849
Stem Cell Reports. 2018 Sep 11;11(3):711-726
pubmed: 30146490
Development. 1994 May;120(5):1097-108
pubmed: 8026323
Adv Exp Med Biol. 2019;1190:201-216
pubmed: 31760646
J Neurocytol. 1995 Oct;24(10):775-81
pubmed: 8586997
Brain Res Mol Brain Res. 1993 Mar;17(3-4):258-68
pubmed: 7685463
Arch Neurol. 1961 Mar;4:323-32
pubmed: 13737358
Mult Scler. 2019 Jun;25(7):891-901
pubmed: 30638421
J Neurobiol. 1999 Sep 15;40(4):497-512
pubmed: 10453052
Lancet. 2017 Dec 2;390(10111):2481-2489
pubmed: 29029896
Nature. 2015 Jun 11;522(7555):216-20
pubmed: 25896324
Brain Pathol. 2001 Jan;11(1):107-16
pubmed: 11145196
J Am Acad Child Adolesc Psychiatry. 2007 Feb;46(2):213-23
pubmed: 17242625
J Neuroendocrinol. 2013 Mar;25(3):229-34
pubmed: 23057474
Cells. 2019 Nov 12;8(11):
pubmed: 31726669
Neuropathol Appl Neurobiol. 2020 Apr;46(3):199-218
pubmed: 31353503
J Neurosci Res. 2001 Oct 15;66(2):254-61
pubmed: 11592121
Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3258-63
pubmed: 11867745
Proc Natl Acad Sci U S A. 2004 Nov 16;101(46):16363-8
pubmed: 15534218
JCI Insight. 2019 Apr 18;4(8):
pubmed: 30996143
Neuroimage. 2016 Jan 15;125:363-377
pubmed: 26525654
Arch Oral Biol. 1983;28(12):1083-7
pubmed: 6582813
Horm Mol Biol Clin Investig. 2017 Nov 28;33(3):
pubmed: 29182513
Adv Exp Med Biol. 1978;100:329-46
pubmed: 80944
Nat Med. 2014 Aug;20(8):954-960
pubmed: 24997607
Neuroimage. 2005 May 15;26(1):132-40
pubmed: 15862213
BMC Neurosci. 2016 Apr 22;17:16
pubmed: 27103572
Mult Scler Relat Disord. 2020 Jun;41:102015
pubmed: 32120028
J Can Dent Assoc. 1989 Nov;55(11):903-7
pubmed: 2684364
Mult Scler. 2017 Oct;23(12):1614-1626
pubmed: 29041865
J Clin Neurosci. 2018 Jan;47:14-19
pubmed: 29066232
Neuroimage. 2006 Jul 15;31(4):1487-505
pubmed: 16624579
J Neurosci Res. 2016 Nov;94(11):1108-15
pubmed: 27638596
Life Sci (1962). 1964 Dec;3:1423-30
pubmed: 14248632
Exp Neurol. 2016 Sep;283(Pt A):330-40
pubmed: 27384502
Methods Mol Biol. 2018;1791:169-177
pubmed: 30006709
Front Neuroanat. 2020 Jun 26;14:33
pubmed: 32676012
Neurobiol Dis. 2019 Oct;130:104501
pubmed: 31226301
J Neurosci Res. 2020 Mar;98(3):491-508
pubmed: 31571267
Nat Neurosci. 2019 May;22(5):700-708
pubmed: 31011227
J Neurochem. 1980 Dec;35(6):1409-17
pubmed: 6160207
J Neurosci Res. 1998 Jul 15;53(2):251-9
pubmed: 9671982
Clin Neurol Neurosurg. 2020 Jun;193:105741
pubmed: 32145678
J Clin Endocrinol Metab. 2012 Dec;97(12):4515-23
pubmed: 22993035
Vitam Horm. 2018;106:253-281
pubmed: 29407438
J Neurosci Methods. 2020 Aug 1;342:108798
pubmed: 32479973
J Neuroimmunol. 2008 Sep 15;201-202:200-11
pubmed: 18672298
Front Neuroendocrinol. 2021 Apr;61:100901
pubmed: 33493504
Nat Neurosci. 2020 Mar;23(3):375-385
pubmed: 32015540
Nat Rev Neurol. 2021 Feb;17(2):88-103
pubmed: 33324001
Exp Neurol. 2008 Aug;212(2):458-67
pubmed: 18572165
J Biomol Screen. 2015 Mar;20(3):382-90
pubmed: 25394729
Exp Biol Med (Maywood). 2015 Sep;240(9):1183-96
pubmed: 25577802
Neurosci Biobehav Rev. 2014 Nov;47:485-505
pubmed: 25445182
Ment Retard Dev Disabil Res Rev. 2006;12(2):157-65
pubmed: 16807907
J Neurosci. 2008 Dec 24;28(52):14189-201
pubmed: 19109501
Acta Neuropathol Commun. 2016 Apr 26;4(1):42
pubmed: 27117475
Mol Genet Metab. 2015 Apr;114(4):494-500
pubmed: 25649058
J Neuroendocrinol. 2014 Nov;26(11):825-33
pubmed: 25131823